Equities

Suven Pharmaceuticals Ltd

SUVENPHAR:NSI

Suven Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,287.70
  • Today's Change7.70 / 0.60%
  • Shares traded74.55k
  • 1 Year change+127.55%
  • Beta1.6610
Data delayed at least 15 minutes, as of Nov 08 2024 10:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The one analyst offering a 12 month price target expects Suven Pharmaceuticals Ltd share price to fall to 1,050.00 in the next year from the last price of 1,281.00.
High-18.0%1,050.00
Med-18.0%1,050.00
Low-18.0%1,050.00

Dividends

Historical dividend information is not available for Suven Pharmaceuticals Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Feb 06, 2023, earnings of 4.23 per share.
Average growth rate-1.78%
Suven Pharmaceuticals Ltd reported annual 2024 earnings of 11.80 per share on May 30, 2024.
Average growth rate-3.68%
More ▼

Revenue history & estimates in INR

Suven Pharmaceuticals Limited had 1st quarter 2025 revenues of 2.31bn. This missed the 3.15bn estimate of the one analyst following the company. This was 33.62% below the prior year's 1st quarter results.
Average growth rate-8.03%
Suven Pharmaceuticals Limited had revenues for the full year 2024 of 10.51bn. This was 21.56% below the prior year's results.
Average growth rate+7.95%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.